Preeclampsia is a systemic vascular disorder of pregnancy and is associated with increased sensitivity to angiotensin II (AngII) and hypertension. The cause of preeclampsia remains unknown. We identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia. RGS5 expression in human myometrial vessels is markedly suppressed in gestational hypertension and/or preeclampsia. In pregnant RGS5-deficient mice, reduced vascular RGS5 expression causes gestational hypertension by enhancing vascular sensitivity to AngII. Further challenge by increasing AngII results in preeclampsia-like symptoms, namely, more severe hypertension, proteinuria, placental pathology, and reduced birth weight. In pregnant heterozygote null mice, treatment with peroxisome proliferator-activated receptor (PPAR) agonists normalizes vascular function and blood pressure through effects on RGS5. These findings highlight a key role of RGS5 at the interface between AngII and PPAR signaling. Because preeclampsia is refractory to current standard therapies, our study opens an unrecognized and urgently needed opportunity for treatment of gestational hypertension and preeclampsia.
INTRODUCTION
Preeclampsia and associated hypertension are serious diseases that affect 5 to 10% of pregnancies (1) . Clinical intervention is limited to preterm delivery and causes long-term cardiovascular problems in the mother and child. Healthy pregnancy requires extensive adaptation of maternal cardiovascular physiology. Despite increased cardiac output and plasma volume, blood pressure decreases due to reduced peripheral resistance (2, 3) . The renin angiotensin system is crucial for these adaptations (4) . Paradoxically, pregnant women develop a marked resistance to pressor effects of infused angiotensin II (AngII), even though components of the renin-angiotensin system increase in the circulation. This is in stark contrast to women with gestational hypertension or preeclampsia, where hyperreactivity to AngII and failure of compensatory reduction in peripheral vascular resistance occur (5, 6) . Pharmacological inhibition of AngII receptor type 1 (ATR1) or angiotensin-converting enzyme (ACE) is contraindicated during pregnancy due to fetopathy (7, 8) , highlighting the need for alternative treatment options.
The mechanism for enhanced AngII sensitivity is poorly understood. Pregnancy-related hypertension and preeclampsia can arise from autoimmune-mediated ATR1 hyperstimulation effected by agonistic anti-ATR1 antibodies (9, 10) . Furthermore, G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR) heterodimer formation, for instance, between ATR1 and bradykinin receptor, has been shown to contribute to AngII hypersensitivity (11) . Alternatively, we hypothesized that AngII signaling could be regulated at a postreceptor level. Regulator of G protein signaling (RGS) molecules tightly control GPCR activation, including ATR1, by acting as intracellular guanosine triphosphatase (GTPase)-activating (GAP) proteins for heterotrimeric G proteins (12) (13) (14) . We recently identified RGS5 as a key regulator of angiogenic vessel remodeling in cancer and critical modulator of cardiovascular function (14, 15) . We therefore speculated that RGS5 might be involved in vascular changes induced by pregnancy. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear transcription factors important in lipid metabolism and glucose homeostasis, and have recently been implicated in blood pressure control (16) . PPARs are also important for early placental development (17) . There is circumstantial evidence that vascular Rgs5 expression correlates with PPAR activation (18, 19) . This establishes a potential link between vascular RGS5 signaling, metabolism, and pregnancy.
Here, we demonstrate a postreceptor regulatory role for RGS5 in pregnancy-induced hemodynamic adaptations. Reduction in RGS5 causes systemic vascular dysfunction leading to high arterial pressure, severe maternal hypertension, and increased preeclampsia risk. PPAR agonists emerge as effective regulators of RGS5 and blood pressure during pregnancy.
RESULTS

RGS5 deficiency causes severe gestational hypertension
To test the hypothesis that RGS5 is involved in pregnancy-related vascular adaptation, we analyzed myometrial arteries from women with normal or hypertensive/preeclamptic pregnancies. RGS5 expression was significantly (P = 0.0015) reduced in hypertensive/preeclamptic pregnancies, suggesting that low RGS5 levels contribute to the pathophysiology ( Fig. 1A and table S1 ). To gain further mechanistic insights, we used RGS5 knockout mice and recorded blood pressure daily throughout pregnancy using telemetry. Nonpregnant RGS5 knockout mice were hypertensive when compared to wild-type controls (14) (Fig. 1B) . With pregnancy, RGS5 deficiency caused more severe gestational hypertension, with daytime mean arterial blood pressure (MAP) of 145 ± 3.7 mmHg around days 12 to 14 of gestation (Fig. 1B) . RGS5 heterozygote knockout mice were normotensive but developed hypertension during pregnancy (116.9 ± 3.7 mmHg, day 12) in a gene dose-dependent manner (Fig. 1B) . During the nocturnal activity phase, MAP values reached 182.6 ± 6.1 mmHg in RGS5 knockout females (Fig. 1, C to E). Activity and heart rate remained unchanged between groups (Fig. 1, C and D, and fig. S1 , A and B), and hypertension was not dependent on genetic background ( Fig. 1E and fig. S1C ). From day 14, MAP decreases but only reaches prepregnancy levels 7 days after delivery (Fig. 1B) . Consistent with a regulatory role during pregnancy, RGS5 levels increase in uterine arteries and peak around day 12 ( Fig. 1, F and G) , whereas mRNA expression of vasoconstrictor and vasodilator receptors remains unchanged between wild-type and RGS5 knockout mice ( fig. S2 , A to E).
RGS5 regulates vascular adaptation during pregnancy
During normal pregnancy, vasodilation reduces systemic vascular resistance and decreases blood pressure. Consistent with gestational hypertension in RGS5-deficient mice, the pregnancy-associated increase in blood flow in femoral and uterine vascular beds is halved in RGS5 knockout females ( Fig. 2A) . Moreover, reactivity to vasoactive factors is altered in uterine, mesenteric, and femoral arteries (Fig. 2, B to E, uterine arteries, and fig. S3 , A to D, mesenteric and femoral arteries). Specifically, in pregnant RGS5-deficient mice, the AngIIevoked reduction in uterine vascular conductance in vivo and constriction of isolated arteries are markedly enhanced (Fig. 2, B and D) . Likewise, endotheliummediated vasodilation of uterine arteries is diminished (Fig. 2, C and E) . Thus, enhanced vasoconstriction and reduced endothelium-mediated vasodilation in RGS5-deficient vessels contribute to reduced blood flow and elevated blood pressure. The passive stress-strain relationship of uterine arteries is specifically altered in pregnant knockout mice, and is shifted to the right, indicating reduced stiffness, consistent with remodeling as observed in small arterioles during hypertension (20) (Fig. 2F, uterine arteries, and fig. S3 , E and F, mesenteric and femoral arteries).
Excessive AngII signaling causes oxidative stress in RGS5-deficient mice Chronic treatment of RGS5 knockout pregnant females with ATR1 antagonists normalizes blood pressure, demonstrating that ATR1 hyperactivation in the absence of RGS5 is responsible for gestational hypertension (Fig. 3A) . AngII activates NADPH (reduced form of Fig. 1 . Loss of RGS5 correlates with preeclampsia in humans and causes gestational hypertension in mice. (A) Relative RGS5 expression (normalized to HPRT mRNA) in human myometrial arteries from normal (n = 13) or hypertensive/ preeclamptic pregnancies (n = 10), mean ± SEM. P value determined by Student's t test. (B) MAP recordings during pregnancy and postpartum in wild-type (WT), RGS5 homozygote (KO), and heterozygote (HET) knockout mice. A summary of three independent radiotelemetry experiments is shown (n = 14 for WT, n = 8 for HET, n = 15 for KO mice). Error bars represent means ± SEM of 30 min recordings/day during daytime. (C and D) Day/night blood pressure recordings and activity as measured by telemetry in conscious (C) days 12 and 13 pregnant, and (D) days 18 and 19 pregnant WT and KO mice (n = 5 for all groups). (E) MAP differences (DMAP) between day and night in 12-and 13-day and 18-and 19-day pregnant females (night peak MAP on pregnancy days 12 and 13: WT 109.1 ± 4.2 mmHg, KO 182.6 ± 6.1 mmHg; pregnancy days 18 and 19, WT 103.2 ± 5.2 mmHg, KO 169.8 ± 3.8 mmHg), mean ± SEM, n = 5 mice for all groups. (F) Relative Rgs5 mRNA expression (normalized to Hprt mRNA) in uterine arteries from nonpregnant (day 0, n = 6 pools of 3 vessels each), pregnant day 6 (n = 4 pools), day 12 (n = 6 pools), and day 18 WT mice (n = 7 pools); mean ± SEM; P value determined by Student's t test. (G) RGS5 protein expression in uterine arteries of WT mice during pregnancy as assessed by immunoblotting. RGS5 protein expression was normalized to tubulin. Three independent experiments were quantified, mean ± SEM. A representative Western blot is shown below the graph.
nicotinamide adenine dinucleotide phosphate) oxidases to generate reactive oxygen species (ROS). Excessive oxidative stress secondary to enhanced AngII signaling in RGS5 knockout vessels could explain endothelial vasodilator dysfunction (21) . Indeed, arteries from day 18 pregnant RGS5 knockout females produce more ROS (Fig. 3B , uterine arteries, and fig. S4A , mesenteric arteries). Treatment of RGS5 knockout mice with the antioxidant apocynin restores vascular responsiveness to acetylcholine (ACh) but not AngII in vivo (Fig. 3 , C and D, uterine arteries, and fig. S4 , B and C, femoral arteries). The nitric oxide (NO) donor sodium nitroprusside (SNP) evokes larger increases in blood flow and vasodilation in arteries from day 18 pregnant RGS knockout mice than wild-type controls (Fig. 3 , E and F, uterine arteries, and fig. S4 , D and E, femoral and mesenteric arteries). Hypersensitivity to SNP can be an indicator of chronic endogenous NO deficiency (22) , and indeed, activation of endothelial nitric oxide synthase (eNOS) in RGS5-deficient arteries is impaired (Fig. 3G) . Moreover, vasodilator-stimulated phosphoprotein (VASP) Ser 239 phosphorylation, a marker for the activity state of the NO/cGMP (guanosine 3′,5′-monophosphate) pathway (23) , is enhanced under SNP stimulation (Fig. 3H) . Collectively, these findings demonstrate a critical role for RGS5 in regulating AngII signaling and systemic and uteroplacental vascular tone in pregnancy.
RGS5 controls vascular adaptation in response to volume loading
The pathological rise in blood pressure in pregnant RGS5-deficient females mimics the kinetics of plasma volume expansion during murine and human pregnancy (24) . Plasma volume expansion during pregnancy in wild-type females is comparable to RGS5 knockout mice. Similarly, weight gain does not differ between genotypes, thus excluding high fluid retention as a cause of MAP elevation in pregnant RGS5 knockout females ( fig. S5, A and B) . Instead, we hypothesized that failure to decrease peripheral resistance when plasma volume increases may cause hypertension on an RGS5-deficient background. To test this, we assessed blood pressure responses to chronic [deoxycorticosterone acetate (DOCA)/salt intake] and acute (saline infusion) hypervolemia. During periods of increased salt intake, elevations of plasma volume, cardiac output, and arterial pressure are expected (25) . However, the rise in MAP after DOCA/salt intake, which is exacerbated in RGS5 knockout mice compared to controls, can be abrogated by ATR1 blockade (Fig. 4A) . Similarly, RGS5 knockout mice demonstrate greater volume-induced (saline infusion) hypertension, which is abolished by ATR1 inhibition, whereas wild-type mice show only mild volume-induced hypertension and nonsignificant reduction with ATR1 blockade (Fig. 4B) . The loss of one Rgs5 gene copy is sufficient to increase the MAP response to DOCA/salt intake and acute volume expansion ( fig. S6, A and B ). These results demonstrate that RGS5 regulates cardiovascular adaptation in response to hypervolemia, which is also an integral part of pregnancy.
RGS5 deficiency predisposes to preeclampsia
Despite hypertension, RGS5 homo-and heterozygote knockout females give birth to normal offspring (Table 1) . However, significantly (P = 0.001) elevated soluble fms-like tyrosine kinase-1 (sFLT-1), a factor that can be released by the ischemic placenta in hypertensive and/or preeclamptic pregnancies (26) , in serum from RGS5 knockout mothers is indicative of underlying placental/vascular abnormalities (27) (Fig. 5A ). To mimic high-risk pregnancies with strongly activated AngII signaling, such as in the presence of ATR1 autoantibodies (9) on an RGS5-deficient background, mice were infused with AngII from days 10 to 18 of pregnancy (28) ; this increased day 18 blood pressure more in hetero-or homozygote knockout mice compared with wild-type mice (Fig. 5B ). Proteinuria was induced with AngII infusion in RGS5-deficient females only (loss of one or two gene copies; Fig. 5C ). Offspring from AngII-treated RGS5 hetero-or homozygote knockout females were more likely to experience intrauterine growth restriction (IUGR) as compared to offspring born to wild-type females ( Fig. 5D and Table 1 ). Similarly, RGS5 deficiency caused a higher incidence of embryonic death with AngII hyperstimulation (Table 1) . Placental weight remained unchanged between groups (fig. S7); however, IUGR correlated with placental abnormalities including reduction in the embryonic labyrinth zone and expansion of the spongiotrophoblast layer ( placentas and further constricted with AngII infusion (Fig. 5 , G and H), indicating that fetal and, hence, placental loss of RGS5 is a confounding factor in inducing IUGR, most likely by contributing to reduced fetal perfusion. However, fetal complications only arose in AngII-infused RGS5 hetero-or homozygote females (for example, maternal −/− × paternal +/+ pregnancies produced 24% dead embryos and IUGR, as compared to asymptomatic pregnancies seen in +/+ maternal × −/− paternal matings; Table 1 ), suggesting that alterations of the reninangiotensin system in conjunction with maternal RGS5 reduction are an important risk factor. This is consistent with human pregnancies where onset of hypertension remote from term increases the risk of preeclampsia (29) .
PPAR agonists act upstream of Rgs5 to abolish gestational hypertension and vessel dysfunction RGS5 heterozygote knockout mice developed hypertension during pregnancy (Fig.  1B) . Given the proposed role of PPARs in increasing vascular Rgs5 expression (18, 19) , we assessed whether PPARg agonist treatment can rescue heterozygote mice from gestational hypertension. Chronic treatment of mice with a PPARg agonist (troglitazone) throughout pregnancy abolished hypertension in heterozygote but not in homozygote RGS5 knockout mice (Fig. 6A) . Troglitazone treatment did not change heart rate ( fig. S8A ). To further evaluate the therapeutic potential, RGS5 heterozygote mice were treated intraperitoneally (ip) or by oral gavage with troglitazone or highly selective PPARg (GW1929) or PPARb/d (GW0742) agonists or a PPARg antagonist (GW9662), from day 10 of pregnancy when hypertension is evident. During the 8 days of treatment in pregnant heterozygote mice, MAP was normalized to wildtype levels ( This establishes an important role of RGS5 in linking AngII and PPAR signaling to cardiovascular adaptation during pregnancy (Fig. 6F) .
Systemic troglitazone treatment of heterozygote pregnant females also increases Rgs5 mRNA expression in day 18 placentas (fig. S9A ). However, prolonged treatment over 25 days was required to normalize the fetal blood supply ( fig. S9B ). Antihypertensive PPARg agonist treatment from mid-to end-term did not induce placental abnormalities or reduce birth weight in RGS5 heterozygote mice (fig. S9, C to F) and may thus be a potential therapy for severe cases of gestational hypertension or preeclampsia. 
DISCUSSION
The mechanisms contributing to peripheral vascular events of pregnancy remain poorly understood. Here, we establish RGS5 as a regulator of peripheral resistance to AngII and identify a mechanism of ATR1 signaling desensitization during pregnancy. In healthy pregnancy, vascular RGS5 concentration increases with plasma volume expansion and antagonizes AngII signaling. In contrast, reduced RGS5 expression causes severe endothelial dysfunction secondary to pathologically enhanced AngII signaling in a sequence of events involving superoxide production, eNOS uncoupling, and impaired NO/cGMP signaling. Systemic vascular dysfunction then causes gestational hypertension and most likely reduces maternal-placental perfusion. This correlates with decreased fetal capillary sizes in RGS5 homozygote or heterozygote embryos, which may contribute to placental inefficiency. Despite vascular abnormalities, RGS5 homozygote and heterozygote knockout females produce normal-size litters. This is consistent with lack of maternal proteinuria or organ damage. The degree of maternal and fetal vascular hyperconstriction and, thus, uteroplacental perfusion in RGS5-deficient mice is strictly gene dose-dependent and only reaches pathological levels when superimposed with enhanced AngII stimulation. This could occur in pregnancies with elevated ATR1-activating autoantibodies, for instance, (9) . Further restriction of blood supply to embryos with enhanced AngII stimulation then results in preeclampsia-like symptoms such as proteinuria, IUGR, and loss of embryos. Although fetal RGS5 deficiency is a confounding factor, IUGR with enhanced AngII stimulation was only observed in mothers with reduced expression of RGS5.
In humans, increased sensitivity to AngII signaling is a hallmark of preeclampsia and also persists postpartum (31) , raising the possibility that it may precede pregnancy and pose an increased risk for pregnancy complications. Indeed, reduced RGS5 expression, as occurs in RGS5 heterozygote mice, triggers gestational hypertension in otherwise asymptomatic mice and increases the risk of preeclampsia. Therefore, our study demonstrates that preexisting, subclinical maternal vascular dysfunction can result in a spectrum of pregnancy-related cardiovascular complications. This may be independent of early placentation events, therefore challenging the dogma that maternal endothelial dysfunction and preeclampsia arise exclusively due to poor placentation (1). Our data thus support the idea that cardiovascular complications arising well after pregnancy may be constitutional rather than consequent upon the hypertensive pregnancy (32, 33) .
So far, RGS molecules have not been linked to pregnancy-induced vascular adaptation or preeclampsia. However, RGS5 expression in human myometrial vessels is reduced in gestational hypertension and/or preeclampsia (Fig. 1A) , which provides clinical support for our murine findings. Another RGS family member, RGS2, blunts AngII signaling in patients with Bartter's/Gitelman's syndrome, who present with normotension or hypotension and reduced peripheral resistance despite high levels of circulating AngII and aldosterone (34) ; this provides evidence for a delicate role of RGS molecules in regulating peripheral vascular resistance in response to increased renin-angiotensin activity.
Our data also show that antihypertensive effects of PPAR agonists during pregnancy are exclusively mediated by RGS5. PPARs are important ) from day 10 to day 18 of pregnancy. MAP was measured in anesthetized mice at day 18 (DMAP untreated versus AngII infusion: WT: 29.9 ± 2.0 mmHg; HET: 43.0 ± 2.8 mmHg; KO: 53.2 ± 3.3 mmHg), mean ± SEM, n = 5 mice per group, average litter size all pregnancies: n = 7. (C) Urinary albumin/creatinine ratio (mg/mg) for all genotypes after AngII infusion, n =12 to 13 mice. (D) Embryo weights at day 18 of pregnancy with or without AngII infusion, mean ± SD, n = 5 mice, 27 embryos per group. (E) Ratio of labyrinth/total placental area, mean ± SD, n = 5 mice, 27 placentas per group. (F) Representative images from hematoxylin and eosin (H&E)-stained placentas from AngII-treated WT, HET, and KO mice, with labyrinth zone delineated in black (left), or aSMA-stained sections (right). sp, spongiotrophoblast layer; la, labyrinthine layer. Scale bar, 1000 mm. (G) Quantification of the total area of fetal capillary lumens in placental labyrinthine layers from untreated or AngII-infused mice of different genotypes, n = 8 mice (three placentas per mouse), mean ± SEM. (H) Representative staining of CD31 + lined fetal vessels in the labyrinthine layer from three independent experiments. One vessel per microscopic field is delineated (dotted line) to illustrate vessel size. Scale bar, 10 mm. KO refers to −/− females and −/− embryos, HET to +/− females and selective analysis of +/− embryos.
in normal pregnancy because of their specific role in trophoblast invasion and placental development (17, 35) . However, the role of PPARs in the maternal and/or uteroplacental vasculature in later pregnancy is less explored. PPARg inhibition during pregnancy impairs uteroplacental blood flow and induces preeclampsia-like symptoms in rats (36, 37) . In contrast, PPARg agonist treatment in a rat model of reduced uterine perfusion improves vascular function and hypertension (38) . There is also emerging evidence that PPAR expression is associated with maternal metabolism and adverse pregnancy outcomes related to obesity and gestational diabetes mellitus (GDM) (39, 40) . Thus, the PPAR-RGS5-AngII signaling network presented here provides insights into how obesity and GDM may be linked to gestational hypertension and preeclampsia; this is important given the rapidly growing prevalence of obesity during pregnancy (41) .
How RGS5 expression is regulated during normal pregnancy is currently unknown. There is evidence for transcriptional regulation of the Rgs5 gene as part of dynamic cardiovascular adaptations to diverse stimuli, such as hypoxia, growth factor expression, or chronic AngII exposure (14, 42, 43) . However, there is no evidence for transcriptional regulation of Rgs5 by GPCR agonists such as AngII (43, 44) , thus making it unlikely that RGS5 is directly regulated by the renin-angiotensin system during pregnancy. Given the direct link between PPAR agonists and Rgs5 vascular transcripts, it is possible that RGS5 expression rises with increasing PPAR activation. PPARg activators such as fatty acids and lipid metabolites are up-regulated in human serum during normal gestation and reduced with preeclampsia (39, 45) . Circulating PPAR activator concentrations could be linked to the dynamic RGS5 expression we report here. Furthermore, gene polymorphisms for both PPARg and RGS5 have been implicated in human essential hypertension (46) (47) (48) (49) and may also increase the risk for pregnancy-related disorders.
Our study suggests that optimal PPAR agonist treatment for RGS5-related hemodynamic maladaptations may be during the second half of pregnancy at the peak of volume expansion. PPARg agonist treatment from mid-to end-term did not induce placental abnormalities or reduce birth weight in our mouse model. Despite earlier clinical setbacks, the use of PPAR agonists remains attractive, and next-generation drugs replacing thiazolidinediones are already in clinical use to treat type II diabetes and female infertility (50, 51) . Current strategies for managing preeclampsia are inadequate and reflect a fundamental lack of understanding of the causes and pathogenesis of the disease (52) . Consistent with other murine gene knockout studies (53) , the RGS5 knockout model described here mimics part of the clinical spectrum and thus addresses only some aspects of the complex mechanisms underlying the disease. Nevertheless, our study identifies mechanisms that potentially contribute to preeclampsia and ). MAP was recorded in anesthetized mice on day 18, mean ± SEM, n = 3 mice per group. (C) Relative Rgs5 mRNA expression (normalized to Hprt mRNA) in uterine arteries from day 18 pregnant WT, untreated HET, or HET mice after troglitazone injection (ip, 10 mg/kg), n = 6 mice for all groups, mean ± SEM. (D and E) Conductance in uterine arteries of untreated and troglitazone-treated HET or KO mice after bolus injection of (D) AngII (10 mg/kg) or (E) ACh (10 mg/kg), mean ± SEM (for ACh, error bars are within symbols), n = 4 mice per group. (F) Schematic summary of the PPAR-RGS5-AngII signaling network in pregnancy: (i) circulating PPAR ligands (35) and components of the renin-angiotensin system such as AngII (6) are up-regulated during normal pregnancy, (ii) activated PPARs increase Rgs5 gene transcription, and (iii) increased RGS5 decreases AngII sensitivity.
provides mechanism-guided treatment options for pregnancy-related hypertensive disorders, which warrant clinical investigation.
Direct targeting of the renin-angiotensin system in the management of pregnancy-related hypertension remains an important but so far unmet clinical need. Our study demonstrates that modulating RGS5 expression with PPAR agonists provides an opportunity to improve hypertension and pregnancy outcomes.
MATERIALS AND METHODS
Study design
The purpose of the study was to demonstrate a specific vascular role of RGS5 in pregnancy. The hypothesis was based on our previous findings that RGS5 regulates angiogenic vessel remodeling and AngII signaling in mice (14, 15) ; both features are integral parts of pregnancy. Human myometrial vessels from healthy pregnancies and women with pregnancy complications (inclusion criteria: gestational hypertension, MAP >105 mmHg, and preeclampsia, hypertension, MAP >105 mmHg, and at least 0.5 g of protein per 24-hour urine collection after week 20 of gestation; exclusion criteria: diabetes, IUGR without hypertension/ proteinuria) were analyzed to test the clinical relevance of RGS5. Human myometrial arteries from pregnant women (table S1) were obtained at delivery after informed written consent. The South Eastern Sydney Local Health District review board approved the human study. Quantitative RGS5 analysis in human samples was done blindly. Mechanistic studies were conducted on RGS5 knockout and wild-type mice of identical genetic background (C3HeBFe) with the exception of one control experiment where RGS5 knockout and wild-type mice bred on a C57BL/6 genetic background were analyzed ( fig. S1C ). All experimental protocols involving mice were approved by the Animal Ethics Committee of the University of Western Australia. No randomization was used in animal experiments. No statistical method was used to predetermine sample size. No data (outliers) were excluded. At least three independent experiments were conducted. All data are presented directly, or as a representative figure, with quantification of experiments. Murine placental histopathology was conducted blindly. Drug studies are based on initial reports demonstrating a correlation between Rgs5 expression and PPARg or PPARd agonist treatment (18, 19) . For clinical translation, drug experiments were conducted with different compounds targeting the same pathway, different application routes (intraperitoneal and oral gavage), and at different intervention times (prophylactic versus therapeutic).
Mice
Homo-or heterozygote RGS5 knockout females (54) on a C3HeBFe background (>30 generations backcrossed) were studied between weeks 8 and 16 of age. MAP in pregnant RGS5 knockout females on a C57BL/ 6 background was analyzed in comparison ( fig. S1C ). Mice were kept under specific pathogen-free conditions at the University of Western Australia. Timed matings were performed using standard operating procedures and mating plugs identified on day 1. On day 18, embryo genotyping with the following RGS5 primers (RGS51: CTCCCTTAATGGACTCACTGAA-GAA, RGS52: ACCATGGATTATCTCCTTTTGAATCT) was performed before placental analyses.
Chemicals and antibodies
The following drugs and doses were used: AngII (Merck Millipore), 10 mg/kg for acute experiments, 1 mg kg −1 day −1 in minipumps, 10 −10 to 10 −5 M for myography; ATR1 antagonist (candesartan, AstraZeneca), 10 mg/ml in drinking water; ACh (Sigma), 10 mg/kg in vivo, 10 −10 to 10 
Western blot analysis
Uterine arteries: Vessels were snap-frozen and pulverized with mortar and pestle under liquid nitrogen, dissolved in 0.1% Triton lysis buffer [10 mM Hepes (pH 7.4), 50 mM sodium pyrophosphate, 50 mM NaF, 5 mM EDTA, 5 mM EGTA, 100 mM Na 3 VO 4 , 50 mM NaCl, 0.1% Triton X-100, 500 mM phenylmethylsulfonyl fluoride, and leupeptin (10 mg/ml)], sonicated, and cleared by centrifugation. One hundred micrograms of protein per lane was separated and transferred onto a nitrocellulose membrane, and the bands were visualized with a chemiluminescence detection system (ECL Western Blotting Detection Reagents, Amersham Biosciences) and quantified. Mesenteric arteries: Ex vivo phosphorylation studies and Western blot analysis were performed as previously described (14) .
Gene expression analysis RNA from uterine or mesenteric arteries, murine placenta (dissected labyrinth layer), or human myometrial arteries was prepared using TRIzol reagent (Invitrogen). Gene expression was quantified by quantitative polymerase chain reaction (qPCR) using the Rotor-Gene Real-Time PCR detection system (Qiagen). All reactions were normalized to hypoxanthineguanine phosphoribosyltransferase (Hprt/HPRT). The following primer sequences were used: Atr1a/b: TGTAAGATCGCTTCGGCCA (forward), AGGTAGCGATCGATGCTGAGA (reverse); Atr2: GCA-TATGTCGGAAATGAATTCTGA (forward), TCGAAAGCCCAC-GATTCACT (reverse); BdkrB1: CGAAGCTTGGCACTTTGTAAGG (forward), AGCCAATGGGAGGAGGAAA (reverse); BdkrB2: CAA-GTCCTCGGGTCTGCTCTT (forward), CGGTGTCTGGGCAGTT-GTC (reverse); EtrA: AACTAACCCTCCGCAGAAACAC (forward), GCGTAATGGTTGTTTCCATCCT (reverse); EtrB: GTGGCTTCT-TGGGGGTATGG (forward), TCTTAGTGGGTGGCGTCATTA (reverse); human HPRT: CGTCTTGCTCGAGATGTGATG (forward), GCACACAGAGGGCTACAATGTG (reverse); mouse Hprt: ACACCT-GCTAATTTTACTGGCAACA (forward), TGGAAAAGCCAAATA-CAAAGCCTA (reverse); human RGS5: CAGAAAACCTCGCTGGACGA (forward), TGAAACTGGCAAGTCCATAGTTGT (reverse); mouse Rgs5: GCTTTGACTTGGCCCAGAAA (forward), CCTGACCAGAT-GACTACTTGATTAGCT (reverse).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay for mouse VEGFR-1/FLT-1 (R&D Systems) was performed according to the manufacturer's instructions.
Blood samples were diluted 1:25. Absorbance was determined at 450 nm and at 540 nm for wavelength correction (BioTek PowerWave XS2). All assays were performed in duplicates, and the protein concentrations were calculated using a standard curve derived from known concentrations of recombinant protein standards.
Histology and immunohistochemistry
Placentas were isolated from day 18 pregnant females, fixed in 10% neutral buffered formalin, and embedded in paraffin. Five-micrometer sections were stained with H&E (Sigma). For aSMA staining, placentas were deparaffinized and stained with primary antibody, and signals were amplified using the Mouse on Mouse (M.O.M.) kit (Vector). For CD31 staining, deparaffinized sections were stained with antibody followed by the ABC kit (Vector) and counterstained with methyl green. Stained sections were photographed with a Nikon microscope (Eclipse Ni), and five random fields per placenta were quantified using NIS-Elements software (Nikon, version 4).
Hemodynamic measurements
Radiotelemetry devices [PA-C10, Data Sciences International (DSI)] were implanted into females as previously described (14) . Ten days later, females were time-mated, and their blood pressure, heart rate, and locomotor activity (counts per minute, as recorded by telemetry device and counted by the data acquisition system) were measured during pregnancy and 7 days postpartum. Data were collected using the Dataquest A.R.T. system, version 4.1 (DSI). Blood pressure was recorded for 30 min/day (starting at 11:00 a.m.). In addition, continuous (15-min sampling/hour) day and night recordings (12-hour light-to-dark cycle) were collected over 24 hours. Seven-day release ALZET Osmotic Pumps (1007D) were implanted subcutaneously as described by the manufacturer at day 10 of pregnancy. Intra-arterial blood pressure under general anesthesia (urethane, 1.1 g/kg) was recorded using a transducer-tipped catheter. Briefly, the right common carotid artery was catheterized with a Millar 1.4-French blood pressure probe and transducer (ADInstruments). The catheter was connected to a Millar transducer amplifier and PowerLab data acquisition system (PowerLab 16/35 and LabChart Pro Data Acquisition Software, ADInstruments). Vasoactive drugs were applied via intravenous bolus injections through a catheter in the femoral vein. Blood flow in femoral and uterine arteries was measured under general anesthesia (urethane, 1.1 g/kg) using the transit time ultrasonic system (Transonic Systems, probe: 0.5 mm PS series). Flow was recorded with a T206 flowmeter (Transonic Systems). Conductance was calculated by dividing the maximal blood flow (ml/s) by the mean arterial pressure (mmHg) recorded with a Millar 1.4-French probe.
Chronic and acute volume expansion Chronic (high salt intake): Mice were implanted with DOCA pellets (Innovative Research of America, 50 mg, 21-day release) following the manufacturer's instructions and provided with 1% (w/v) NaCl in their drinking water. Intra-arterial blood pressure was measured after 3 weeks in anesthetized mice. Acute (saline infusion): The volume expansion protocol was modified from (55) . Mice were anesthetized (urethane, 1.1 g/kg), and the right common carotid artery was catheterized with a Millar 1.4-French blood pressure probe and transducer to record blood pressure throughout the procedure. A release catheter was introduced into the bladder. Mice were infused with lactated Ringer's solution with 4.5% bovine serum albumin at a rate of 4.3 ml g −1 hour −1 through the femoral artery using an infusion pump (AL-2000, World Precision Instruments Inc.) for 15 min. This was followed by a higher infusion rate of 114 ml g −1 hour −1 for 30 min, which results in a volume increase corresponding to about 3% of body weight (55). The infusion rate was then lowered again to 4.3 ml g −1 hour −1 for 15 min. ATR1 inhibitor was provided via bolus injection through the femoral vein.
NADPH oxidase activity
Superoxide production in mesenteric and uterine arteries was measured using lucigenin-enhanced chemiluminescence. Arteries of 3-mm length and equal diameter were dissected using a graticule microscopic eyepiece. Vessels were preincubated in carbonated Krebs buffer containing NADPH (100 mM) alone or in the presence of AngII (100 mM) or apocynin (100 mM) for 30 min at 37°C in a 96-well plate (white, flat bottom, Nunc). Solutions were replaced with lucigenin (5 mM)-containing buffers, and bioluminescence was detected in a microplate reader every second for 30 min (PHERAstar, BMG Labtech). Solutions without vessels served as control.
Determination of plasma volume
Plasma volume was determined by Evans blue dye solution as published (56) . After measurement of baseline absorbance at 620 nm, 30 ml of Evans blue (5 mg/ml) (Sigma) saline solution was injected into the tail vein of pregnant mice at the indicated days. After 10 and 30 min, blood samples were collected by tail-vein puncture for determination of circulating Evans blue concentration. Plasma was separated by centrifugation, and Evans blue absorbance was read at 620 nm at a 1:5 dilution with a NanoDrop ND-1000 spectrophotometer. Plasma Evans blue concentration was calculated by extrapolation from an Evans blue standard curve prepared in mouse plasma and was expressed in microliter per gram body weight.
Vascular reactivity and stress-strain relationship Artery reactivity: First-order mesenteric or uterine arteries 1 to 2 mm in length were mounted on a four-channel wire myograph (Danish MyoTechnology) as described (14) . Contractions are expressed as percentage of the contraction evoked by high potassium physiological saline solution (KPSS, isotonic replacement of Na + with K + ). ACh-induced relaxation was assessed in arteries submaximally (70% of maximum) constricted with PE, and relaxation was expressed as the percent decrease from preconstriction levels. Curves were constructed using Prism (v.5.0; GraphPad Software), and sigmoidal curves were fitted to the data using the least squares method. Passive mechanical wall properties were assessed in femoral, mesenteric, and uterine arteries (3 to 4 mm long) mounted on a pressure myograph (Living Systems Instrumentation) as described previously (14) . Briefly, arteries were continuously superfused at 15 ml/min with zero-Ca 2+ physiological saline solution containing EGTA (2 mM) bubbled with 95% O 2 , 5% CO 2 at 36°C. Each artery was pressurized from 0 to 200 mmHg in 10-mmHg increments. Arterial dimensions (length, outside diameter, and wall thickness) were measured at each 10-mmHg increment. Wall stress and strain were derived: wall stress (kPa) = (intraluminal pressure × internal diameter)/(2 × wall thickness); wall strain = (internal diameter − internal diameter extrapolated to 5 mmHg pressure)/internal diameter extrapolated to 5 mmHg pressure.
Statistics
All data are presented as means ± SEM or means ± SD as indicated in the figure legends, and numbers of mice or tissue samples per group (n) are provided in figure legends. Comparisons between groups were performed by one-or two-way analysis of variance (ANOVA) followed by Tukey post hoc test for significance, unless stated otherwise in figure legends. A P value ≤0.05 was considered significant.
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